Skip to content
value.today
Graphite Bio, Inc. logo

Graphite Bio, Inc.

Formerly Longbow Therapeutics Inc.

Total raised
$151 M
1 round on record
Latest round
$151 M
Mar 2021
First round on record
Mar 2021
Today
Went public
See the company page

Graphite Bio, Inc. is listed today as LENZ Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Graphite Bio, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2021$151 MNo. 1$50 to $250 million

Graphite Bio, Inc.: Raise no. 1, Mar 2021

Investors in this round

35 investors had bought by the notice of Mar 19, 2021: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Graphite Bio, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$151 M of $151 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Josh Lehrer · Executive Officer, Director
  • Katherine Stultz · Executive Officer
  • Philip Gutry · Executive Officer
  • Abraham Bassan · Director
  • Carlo Rizzuto · Director
  • Jerel Davis · Director
  • Joe Jimenez · Director
  • Maria Grazia Roncarolo · Director
  • Matthew Porteus · Director
  • Perry Karsen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Josh Lehrer, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 19, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company LENZ Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: License revenue $17.50 million (92%).

    Annual report (SEC XBRL) · Dec 2025

  • Graphite Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2021).

    SEC Form D · Mar 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2021

Products and services#

No products or services of Graphite Bio, Inc. are on record.

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Graphite Bio, Inc.
InvestorKindAmountRoundRoleSource
436, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Joseph JimenezPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2021)SEC Form 3
Joshua Lehrer-GraiwerPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2021)SEC Form 3
Katherine V. StultzPersonnot statednot statedHeld Series B preferred stock (Form 3, 2021)SEC Form 3
Perry A. KarsenPersonnot statednot statedHeld Series B preferred stock, director (Form 3, 2021)SEC Form 3
Phil GutryPersonnot statednot statedHeld Series B preferred stock (Form 3, 2021)SEC Form 3
Samsara BioCapital, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Versant Vantage II GP-GP, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Versant Vantage II GP, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Versant Vantage II, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Versant Venture Capital VI, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Versant Ventures VI GP-GP, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Versant Ventures VI GP, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 35 investors.

Largest shareholders today

Institutions holding LENZ Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Graphite Bio, Inc.
NameRoleNamed in
Josh LehrerExecutive officerMar 2021
Katherine StultzExecutive officerMar 2021
Philip GutryExecutive officerMar 2021
Abraham BassanDirectorMar 2021
Carlo RizzutoDirectorMar 2021
Jerel DavisDirectorMar 2021
Joe JimenezDirectorMar 2021
Josh LehrerDirectorMar 2021
Maria Grazia RoncaroloDirectorMar 2021
Matthew PorteusDirectorMar 2021
Perry KarsenDirectorMar 2021

Went public since 2021. Its SEC number is that of a company listed on a stock exchange.